News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,134 Results
Type
Article (13759)
Company Profile (101)
Press Release (251274)
Section
Business (88038)
Career Advice (465)
Deals (15342)
Drug Delivery (67)
Drug Development (36601)
Employer Resources (49)
FDA (6288)
Job Trends (6196)
News (150203)
Policy (14025)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Adcomms (6)
Allergies (32)
Alliances (23211)
ALS (36)
Alzheimer's disease (385)
Antibody-drug conjugate (ADC) (36)
Approvals (6326)
Artificial intelligence (101)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (578)
Cardiovascular disease (69)
Career advice (407)
Career pathing (11)
CAR-T (20)
Cell therapy (83)
Cervical cancer (4)
Clinical research (30867)
Collaboration (322)
Compensation (132)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (116)
Cystic fibrosis (35)
Data (595)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1316)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32071)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37392)
Executive appointments (355)
FDA (6678)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (204)
Gene editing (37)
Generative AI (8)
Gene therapy (98)
GLP-1 (339)
Government (1285)
Grass and pollen (2)
Guidances (15)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (10)
Immunology and inflammation (34)
Indications (12)
Infectious disease (789)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (44)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (78)
Lymphoma (51)
Machine learning (1)
Management (16)
Manufacturing (142)
MASH (31)
Medical device (1275)
Medtech (1277)
Mergers & acquisitions (9654)
Metabolic disorders (246)
Multiple sclerosis (19)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (553)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (672)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (42)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28862)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8032)
Phase II (13057)
Phase III (11723)
Pipeline (398)
Podcasts (46)
Policy (58)
Postmarket research (1401)
Preclinical (3207)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (157)
Real estate (2633)
Recruiting (17)
Regulatory (10083)
Reports (14)
Research institute (564)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (690)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6819)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (80)
Last 7 days (261)
Last 30 days (968)
Last 365 days (12094)
2025 (2980)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20087)
Australia (2602)
California (1627)
Canada (871)
China (228)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39348)
Florida (303)
Georgia (35)
Idaho (9)
Illinois (183)
India (14)
Indiana (128)
Iowa (1)
Japan (86)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1403)
Michigan (28)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (715)
New Mexico (7)
New York (474)
North Carolina (377)
North Dakota (2)
Northern California (672)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (410)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (690)
Tennessee (34)
Texas (218)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (111)
Wisconsin (14)
265,134 Results for "osmotica pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference.
December 20, 2021
·
1 min read
Pharm Country
Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary shares.
October 6, 2021
·
4 min read
Business
Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets.
November 11, 2021
·
1 min read
Business
Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update
Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced business highlights and financial results for the three months ended September 30, 2021.
November 15, 2021
·
19 min read
Deals
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant.
October 13, 2021
·
4 min read
Business
Osmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business Update
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended June 30, 2021.
August 16, 2021
·
18 min read
Pharm Country
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals, plc, a fully integrated biopharmaceutical company, announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC pursuant to which Alora will acquire Osmotica’s portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 million.
June 25, 2021
·
7 min read
Pharm Country
Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
Osmotica Pharmaceuticals plc announced that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows.
January 6, 2022
·
1 min read
Deals
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that it has closed the previously announced sale of its legacy business, including certain of the Company’s US subsidiaries dedicated to the legacy business and its Marietta, Georgia, manufacturing facility, to Alora Pharmaceuticals, LLC, effective August 27, 2021.
August 30, 2021
·
5 min read
Pharm Country
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows: Date: Thursday, November 18, 2021
November 15, 2021
·
1 min read
1 of 26,514
Next